Eligibility of patients with brain metastases for phase I trials: time for a rethink?

The Lancet Oncology

Volumn 9, Issue 10, 2008, Pages 1012-1017

  Carden, Craig P ^a   Agarwal, Roshan ^a   Saran, Frank ^a   Judson, Ian R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; ERLOTINIB; GEFITINIB; IRINOTECAN; SORAFENIB; STEROID; TEMOZOLOMIDE;

ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; HUMAN; NEUROIMAGING; PATIENT CODING; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SCREENING; SYSTEMIC THERAPY;

EID: 52949136302     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70257-2     Document Type: Note

References (33)

1. Crivellari D., Pagani O., Veronesi A., et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12 (2001) 353-356
2. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., and Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18 (2007) 23-28
3. Lin N.U., and Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 13 (2007) 1648-1655
4. Yokota A., Kimura S., Masuda S., et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109 (2007) 306-314
5. Omuro A.M., Kris M.G., Miller V.A., et al. High incidence of disease recurrence in the brain and leptomeninges in patients with non small cell lung carcinoma after response to gefitinib. Cancer 103 (2005) 2344-2348
6. US Food and Drug Administration. The 1938 Food, Drug, and Cosmetic Act. http://www.fda.gov/oc/history/historyoffda/section2.html (accessed Aug 12, 2008).
7. Bulpitt C. Randomised controlled clinical trials (1992), Kluwer Academic Publishing, London
8. Greenwood D.T., and Todd A.H. From laboratory to clinical use. In: Johnson F.N., and Johnson S. (Eds). Clinical trials (1977), Blackwell Scientific Publications, Oxford 13-35
9. Zimm S., Wampler G.L., Stablein D., Hazra T., and Young H.F. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48 (1981) 384-394
10. Bradley K.A., and Mehta M.P. Management of brain metastases. Semin Oncol 31 (2004) 693-701
11. Posner J.B. Management of brain metastases. Revue Neurol 148 (1992) 477-487
12. Gaspar L.E., Scott C., Murray K., et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Rad Oncol Biol Phys 47 (2000) 1001-1006
13. Regine W.F., Rogozinska A., Kryscio R.J., et al. Recursive partitioning analysis classifications I and II: applicability evaluated in a randomized trial for resected single brain metastases. Am J Clin Oncol 27 (2004) 505-509
14. Nieder C., Andratschke N., Grosu A.L., et al. Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases. Strahlenther Onkol 179 (2003) 16-20
15. Carden C.P., Larkin J.G., and Rosenthal M.A. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol 10 (2008) 624-630
16. Suzuki H., Toyoda S., Muramatsu M., et al. Spontaneous haemorrhage into metastatic brain tumours after stereotactic radiosurgery using a linear accelerator. J Neurol Neurosurg Psychiatry 74 (2003) 908-912
17. Sperling M.R., and Ko J. Seizures and brain tumors. Semin Oncol 33 (2006) 333-341
18. Baker Jr. H.L., Campbell J.K., Houser O.W., et al. Early experience with the EMI scanner for study of the brain. Radiology 116 (1975) 327-333
19. Davis P.C., Hudgins P.A., Peterman S.B., et al. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 12 (1991) 293-300
20. Gasper L.E., Gutin P.H., Rogers L., et al., for the Expert Panel on Radiation Oncology-Brain Metastases Work Group. Pre-irradiation evaluation and management of brain metastases. In: Reston V.A. (Ed) (2005), American College of Radiology (ACR). http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=8303& nbr=4635 (accessed Sept 7, 2008).
21. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608
22. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
23. Meisel J.A., Guthrie K.A., Breslow N.E., et al. Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group. Int J Radiat Oncol Biol Phys 44 (1999) 579-585
24. Kwee S.A., Ko J.P., Jiang C.S., et al. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology 244 (2007) 557-565
25. Omuro A.M., Leite C.C., Mokhtari K., et al. Pitfalls in the diagnosis of brain tumours. Lancet Neurol 5 (2006) 937-948
26. Falk S.J., Girling D.J., White R.J., et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 325 (2002) 465
27. Miller K.D., Weathers T., Haney L.G., et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14 (2003) 1072-1077
28. Gerstner E.R., and Fine R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25 (2007) 2306-2312
29. Popat S., Hughes S., Papadopoulos P., et al. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56 (2007) 135-137
30. Ceresoli G.L., Cappuzzo F., Gregorc V., Bartolini S., Crino L., and Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15 (2004) 1042-1047
31. Henderson C.A., Bukowski R.M., Stadler W.M., et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). Proc Am Soc Clin Oncol 25 suppl 18 (2007) abstr 15506.
32. Amaravadi R., Schuchter L.M., McDermott D.F., et al. Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. Proc Am Soc Clin Oncol 25 suppl 18 (2007) abstr 8527.
33. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729